Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)

Ophthalmology

Volumn 114, Issue 12, 2007, Pages 2179-2182

  Bakri, Sophie J ^a   Snyder, Melissa R ^a   Reid, Joel M ^a   Pulido, Jose S ^a   Ezzat, Mohamed K ^a   Singh, Ravinder J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; ENUCLEATION; HALF LIFE TIME; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SERUM; TISSUE LEVEL; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; HALF-LIFE; MALE; RABBITS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 36549039554     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.09.012     Document Type: Article

References (15)

1. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
2. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
3. Rosenfeld P.J., Moshfeghi A.A., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36 (2005) 331-335
4. Rich R.M., Rosenfeld P.J., Puliafito C.A., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
5. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
6. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 (2005) 336-339
7. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
8. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (2006) 275-278
9. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
10. Bakri S.J., Donaldson M.J., and Link T.P. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. [letter]. Eye 20 (2006) 1474-1475
11. Bakri S.J., Snyder M.R., Reid J.M., et al. Pharmacokinetics of intravitreal bevacizumab. (Avastin). Ophthalmology 114 (2007) 855-859
12. Gaudreault J., Fei D., Rusit J., et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46 (2005) 726-733
13. Iyer M.N., He F., Wensel T.G., et al. Clearance of intravitreal moxifloxacin. Invest Ophthalmol Vis Sci 47 (2006) 317-319
14. Fauser S., Kalbacher H., Alteheld N., et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 242 (2004) 582-586
15. Scholes G.N., O'Brien W.J., Abrams G.W., and Kubicek M.F. Clearance of triamcinolone from vitreous. Arch Ophthalmol 103 (1985) 1567-1569